On the other hand, bevacizumab – a monoclonal antibody that inhibits angiogenesis by targeting VEGF-A – cannot penetrate the BBB, and thus its efficacy is limited, resulting in no improvement in the overall survival of GBM patients39,40. The gene discussed is VEGFA; the disease is glioblastoma.